Cardiol Therapeutics Inc Class A
🇺🇸XNAS.CRDLUnited StatesHealthcare
Price$1.71-0.02 (-1.16%)
Latest anomalies
Negative 2 detected in the last 120 days
- High: 1
- Medium: 2
- Low: 0
Asset turnover: declining while the industry median improves
Asset turnover: below the 10th percentile of its industry and country peers
PEG ratio: a sudden spike above its trailing quarter average
Free with a Finzer account.
Profile
- Healthcare
- Drug Manufacturers - Specialty & Generic
- United States
Identity
- Exchange
- Nasdaq . XNAS
- Type
- Stock
- ISIN
- CA14161Y2006
- CUSIP
- Not reported
Company
- Employees
- 18
- Headquarters
- Oakville, United States
- Website
- https://www.cardiolrx.com
Market
- Shares outstanding
- 121.5M
- Market cap
- $150.01M
Key dates
- Next earnings
- Nov 12, 2026
Highlights
- Market cap
- $150.01M
- EPS LTM
- -CA$0.45
- P/E LTM
- -3.02
- Div yield
- Not reported
Fundamentals (LTM)
- Revenue
- CA$00%unchanged year on year
- Net income
- -CA$37.55M-27.99%down year on year
- Gross margin
- Not reported
- Free cash flow
- -CA$25.1M-16.19%down year on year
Latest news
Business summary
Cardiol Therapeutics Inc Class A is a company in the healthcare sector, listed on Nasdaq (United States) under the ticker CRDL. Its market capitalisation is $150.01M, from 121.5M shares outstanding, as of . Across the 250 trading sessions to the shares traded between $0.88 and $2.34, and the last close of $1.71 sits 57% of the way up that range. The company is headquartered in Oakville, United States, and employs about 18 people. This is the Nasdaq listing of Cardiol Therapeutics Inc Class A; its primary listing is CRDL on Toronto Stock Exchange.
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.